Matches in SemOpenAlex for { <https://semopenalex.org/work/W2891585810> ?p ?o ?g. }
Showing items 1 to 83 of
83
with 100 items per page.
- W2891585810 endingPage "e23066" @default.
- W2891585810 startingPage "e23066" @default.
- W2891585810 abstract "e23066 Background: Proteasome as a hub protease of the ubiquitin proteasome pathway is an established anticancer drug target. Several drugs that inhibit proteasome are currently used to successfully treat aggressive blood cancers. These drugs are based on their competition with protein substrates of proteasome. However, efficacy of these drugs toward solid cancers is inadequate. Besides, the side effects and developing drug resistance are increasingly hampering the therapy. Therefore, there is an unmet challenge to develop new types of proteasome targeting compounds that are efficient against solid cancers and utilize other mechanisms to stop proteasome. Here we present a compound with a novel molecular mechanism, potentially bypassing limitations of the available drugs. Methods: We rationally designed and synthesized a series of small molecule “B” compounds, derivatives of a binding domain of seco-rapamycin that noncompetitively interfere with peptidase activities of proteasome. We tested effects of the compounds in vitro on purified proteasome, in cellulo with selected cancer cell lines and in a xenograft mouse model of prostate cancer. Results: We found that compound B1 binds to the catalytic core of proteasome far from the catalytic sites, destabilizes assembly of the 26S proteasome responsible for digest of polyUb substrates and allosterically inhibits its proteolytic activities. Molecularly, B1 impedes the gating mechanism responsible for substrate uptake as found with AFM. Tryptophan fluorescence indicates that B1 changes proteasome fold and the binding mode of competitive inhibitors. B1 substantially decreases viability of selected cancer cell lines and shifts their mechanical phenotype toward noncancerous status. B1 synergizes with bortezomib decreasing the IC50 5-10 fold. In a xenograft hormone resistant prostate cancer model, B1 treatment leads to shrinkage of the tumor size, decreases enumeration of aggressive, EpCAM+ CTCs and shifts the macrophage profile toward predator M1 type. Conclusions: B1 compounds constitute a new class of noncompetitive allosteric inhibitors of proteasome that could be useful to develop to treat aggressive prostate cancers alone or in synergy with competitive inhibitors." @default.
- W2891585810 created "2018-09-27" @default.
- W2891585810 creator A5009438194 @default.
- W2891585810 creator A5013241382 @default.
- W2891585810 creator A5018452470 @default.
- W2891585810 creator A5042702595 @default.
- W2891585810 creator A5049119185 @default.
- W2891585810 creator A5052675055 @default.
- W2891585810 creator A5059724481 @default.
- W2891585810 creator A5060124281 @default.
- W2891585810 creator A5077002374 @default.
- W2891585810 creator A5086816415 @default.
- W2891585810 date "2017-05-20" @default.
- W2891585810 modified "2023-09-23" @default.
- W2891585810 title "Anticancer applications of allosteric inhibitors of proteasome." @default.
- W2891585810 doi "https://doi.org/10.1200/jco.2017.35.15_suppl.e23066" @default.
- W2891585810 hasPublicationYear "2017" @default.
- W2891585810 type Work @default.
- W2891585810 sameAs 2891585810 @default.
- W2891585810 citedByCount "1" @default.
- W2891585810 countsByYear W28915858102021 @default.
- W2891585810 crossrefType "journal-article" @default.
- W2891585810 hasAuthorship W2891585810A5009438194 @default.
- W2891585810 hasAuthorship W2891585810A5013241382 @default.
- W2891585810 hasAuthorship W2891585810A5018452470 @default.
- W2891585810 hasAuthorship W2891585810A5042702595 @default.
- W2891585810 hasAuthorship W2891585810A5049119185 @default.
- W2891585810 hasAuthorship W2891585810A5052675055 @default.
- W2891585810 hasAuthorship W2891585810A5059724481 @default.
- W2891585810 hasAuthorship W2891585810A5060124281 @default.
- W2891585810 hasAuthorship W2891585810A5077002374 @default.
- W2891585810 hasAuthorship W2891585810A5086816415 @default.
- W2891585810 hasConcept C104317684 @default.
- W2891585810 hasConcept C161624437 @default.
- W2891585810 hasConcept C166342909 @default.
- W2891585810 hasConcept C181199279 @default.
- W2891585810 hasConcept C185592680 @default.
- W2891585810 hasConcept C203014093 @default.
- W2891585810 hasConcept C25602115 @default.
- W2891585810 hasConcept C27740335 @default.
- W2891585810 hasConcept C2776364478 @default.
- W2891585810 hasConcept C2777478702 @default.
- W2891585810 hasConcept C2778367456 @default.
- W2891585810 hasConcept C502942594 @default.
- W2891585810 hasConcept C55493867 @default.
- W2891585810 hasConcept C71924100 @default.
- W2891585810 hasConcept C98274493 @default.
- W2891585810 hasConceptScore W2891585810C104317684 @default.
- W2891585810 hasConceptScore W2891585810C161624437 @default.
- W2891585810 hasConceptScore W2891585810C166342909 @default.
- W2891585810 hasConceptScore W2891585810C181199279 @default.
- W2891585810 hasConceptScore W2891585810C185592680 @default.
- W2891585810 hasConceptScore W2891585810C203014093 @default.
- W2891585810 hasConceptScore W2891585810C25602115 @default.
- W2891585810 hasConceptScore W2891585810C27740335 @default.
- W2891585810 hasConceptScore W2891585810C2776364478 @default.
- W2891585810 hasConceptScore W2891585810C2777478702 @default.
- W2891585810 hasConceptScore W2891585810C2778367456 @default.
- W2891585810 hasConceptScore W2891585810C502942594 @default.
- W2891585810 hasConceptScore W2891585810C55493867 @default.
- W2891585810 hasConceptScore W2891585810C71924100 @default.
- W2891585810 hasConceptScore W2891585810C98274493 @default.
- W2891585810 hasIssue "15_suppl" @default.
- W2891585810 hasLocation W28915858101 @default.
- W2891585810 hasOpenAccess W2891585810 @default.
- W2891585810 hasPrimaryLocation W28915858101 @default.
- W2891585810 hasRelatedWork W1966528856 @default.
- W2891585810 hasRelatedWork W1985023043 @default.
- W2891585810 hasRelatedWork W2031286395 @default.
- W2891585810 hasRelatedWork W2050290922 @default.
- W2891585810 hasRelatedWork W2133565927 @default.
- W2891585810 hasRelatedWork W2151526425 @default.
- W2891585810 hasRelatedWork W2162023777 @default.
- W2891585810 hasRelatedWork W2385905373 @default.
- W2891585810 hasRelatedWork W2891585810 @default.
- W2891585810 hasRelatedWork W4361249469 @default.
- W2891585810 hasVolume "35" @default.
- W2891585810 isParatext "false" @default.
- W2891585810 isRetracted "false" @default.
- W2891585810 magId "2891585810" @default.
- W2891585810 workType "article" @default.